The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare
it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple
myeloma.
People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk
for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma
cells, which are an important part of the immune system. Patients with active multiple
myeloma generally require treatment but there are currently no approved therapies for
smoldering multiple myeloma.
The names of the study drugs involved in this study are:
- Teclistamab
- Lenalidomide (also called Revlimid)
- Dexamethasone (also called Decadron)